CLAIMS

1. Use of ~~A~~an oxytocin receptor agonist ~~for~~ use in the preparation of a medicament for treatment or prevention of dysphagia in a subject suffering from an autonomic nervous system dysfunction.

2. The ~~oxytocin receptor agonist for~~ use according to claim 1 wherein the dysphagia is characterized by oropharyngeal and/or esophageal dysmotility.

3. The ~~oxytocin receptor agonist for~~ use according to claim 1 or 2 wherein the dysphagia is related to solids and/or liquids, preferably both.

4. The ~~oxytocin receptor agonist for~~ use according to any one of claims 1 to 3 wherein the subject suffers from a neurodevelopmental disorder.

5. The ~~oxytocin receptor agonist for~~ use according to any one of claims 1 to 4 wherein the subject suffers from a hypothalamic dysfunction.

6. The ~~oxytocin receptor agonist for~~ use according to claim 4 or 5 wherein the subject suffers from a genetic neurodevelopmental disorder, preferably selected from the group consisting of Prader-Willi syndrome and Prader-Willi like syndromes, fragile-X syndrome, DiGeorge/22q11.2 Deletion Syndrome, Down syndrome, Rett syndrome, Noonan syndrome, CHARGE syndrome, Kabuki syndrome, Troyer syndrome, Christianson syndrome, Smith-Magenis syndrome, Alstrom syndrome, syndromic obesity, familial dysautonomia, and Williams syndrome.

7. The ~~oxytocin receptor agonist for~~ use according to claim 4 or 5 wherein the subject suffers from a neurodevelopmental disorder selected from the group consisting of autistic spectrum disorder, cerebral palsy, fetal alcohol spectrum disorder and intellectual disability.

8. The ~~oxytocin receptor agonist for~~ use according to any one of preceding claims, wherein the subject is at least 6 months old, preferably at least one year old and is under food diversification transition or is already under diversified diet.

9. The ~~oxytocin receptor agonist for~~ use according to any one of preceding claims wherein the subject is a toddler, a child or a teenager.

10. The ~~oxytocin receptor agonist for~~ use according to any one of preceding claims, wherein dysphagia is characterized by at least one of the following clinical signs:
- pharyngeal or esophageal stasis,
- pharyngeal or esophageal residues,
- abnormal closer of esophageal sphincters, in particular upper esophageal sphincter,
- esophageal distention preferably upper esophageal distention or megaesophagus,
- propulsive troubles,
- delay of swallowing initiation
- desynchronization with the respiratory cycle,
- penetration, inhalation, including silent inhalation
- prolonged or slow esophageal transit,
- decreased peristalsis, and
- nasopharyngeal or esophageal reflux

and wherein said clinical signs are optionally evaluable by videofluoroscopy.

11. The ~~oxytocin receptor agonist for~~ use according to any one of preceding claims wherein the subject has experimented, experiments or is at risk of experimenting one or several of the following disorders: esophageal food bolus obstruction, pulmonary aspiration, recurrent pulmonary infection, aspiration pneumonia, choking, regurgitations, nasal regurgitation and meryscism.

12. The ~~oxytocin receptor agonist for~~ use according to any one of preceding claims, wherein said oxytocin receptor agonist is selected from the group consisting of oxytocin, carbetocin, [Thr^4]OT, HO[Thr^4]OT, [Thr^4, Gly^7]OT, HO[Thr^4, Gly^7]OT, Lipo-oxytocin-1 (LOT-1), demoxytocin, merotocin, demoxytocin, lipo-oxytocin-1 (LOT-1), TC OT 39, and WAY-267464. LIT-001.

13. Use of Oxytocin in the preparation of a medicament for ~~use in the~~ treatment of dysphagia in a subject suffering from a neurodevelopmental disorder.

14. ~~Oxytocin for~~The use according to claim 13, wherein the neurodevelopmental disorder is Prader-Willi syndrome or a Prader-Willi like disorder.

15. ~~Oxytocin for~~The use according to claim 14, wherein the subject is at least 6 months old and is under food diversification transition or is already under diversified diet.

16. ~~Oxytocin for~~The use according to claim 13 or 14, wherein the subject is at least one year old.

17. ~~Oxytocin for~~The use according to any one of claims 13-16, wherein the subject suffers from silent dysphagia.

18. ~~Oxytocin for~~The use according to any one of claims 13-17, wherein~~ch~~ the oxytoxin is to be administered by intranasal route, preferably at a daily dosage from 2 IU to 48 IU.